Vlad Adrian Alexandrescu, MD, PhD; Jos C. van den Berg, MD, PhD; Arnaud Kerzmann, MD; Evelyne Boesmans, MD; Vincent Tchana-Sato, MD
This review examines the current evidence on macrovascular and microvascular interactions between CLTI and DPN and evaluates their implications for the contemporary management of the neuroischemic DF.
This review examines the current evidence on macrovascular and microvascular interactions between CLTI and DPN and evaluates their implications for the contemporary management of the neuroischemic DF.
Jaap J. van Netten, PhD; Sicco A. Bus, PhD, MSc; Marcel G. W. Dijkgraaf, PhD
The authors howcase potential shortcomings in health-economic modeling studies in diabetes-related foot disease and provide the reader with the knowledge to better assess and understand those studies.
The authors howcase potential shortcomings in health-economic modeling studies in diabetes-related foot disease and provide the reader with the knowledge to better assess and understand those studies.
The authors evaluate the survival duration and symptom control outcomes of patients with CLTI who were deemed unsuitable for further revascularization and opted for conservative wound management instead of major amputation.
The authors evaluate the survival duration and symptom control outcomes of patients with CLTI who were deemed unsuitable for further revascularization and opted for conservative wound management instead of major amputation.
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
SAN CLEMENTE, CA — Reflow Medical, Inc. announces that the Medical University of Graz has enrolled the first patient in the DEEPER CHALLENGE clinical trial. This investigator-initiated, single-center, single-arm, prospective study, supported...
HELSINKI, March 12, 2026 (GLOBE NEWSWIRE) -- Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant...
HELSINKI, March 12, 2026 (GLOBE NEWSWIRE) -- Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and anticoagulant...
